Drugs that contain Lanreotide Acetate
1. Somatuline Depot patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5595760 | IPSEN PHARMA | Sustained release of peptides from pharmaceutical compositions |
Mar, 2020
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-156) | Sep 15, 2024 |
| New Indication(I-754) | Sep 15, 2020 |
| New Indication(I-701) | Dec 19, 2017 |
| Orphan Drug Exclusivity(ODE-82) | Dec 16, 2021 |
| Orphan Drug Exclusivity(ODE) | Aug 30, 2014 |
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2012 |
| New Dosing Schedule(D-131) | Mar 04, 2014 |
NCE-1 date: 31 August, 2011
Market Authorisation Date: 30 August, 2007
Treatment: Method of administering lanreotide acetate
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
SOMATULINE DEPOT family patents
